Chi Sheng Pharma & Biotech Co (ROCO:4111) Piotroski F-Score: 7 (As of Jul. 15, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4111 Chi Sheng Pharma & Biotech Co Ltd ROCO:4111
84 GF Score
Price NT$30.15
GF Value NT$33.14
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Chi Sheng Pharma & Biotech Co Piotroski F-Score?

Chi Sheng Pharma & Biotech Co ROCO:4111 +0.33% 84 Piotroski F-Score is 7 as of Jul. 15, 2026, which is at its 10-year median of 7.00. GuruFocus rates ROCO:4111 with a GF Score™ of 84/100 and a GF Value™ of NT$33.14 (Fairly Valued). The stock has 1 warning sign investors should review. Among 802 Medical Devices & Instruments companies, Chi Sheng Pharma & Biotech Co ranks better than 92.52% on this metric.

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Chi Sheng Pharma & Biotech Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Chi Sheng Pharma & Biotech Co's Piotroski F-Score or its related term are showing as below:

ROCO:4111' s Piotroski F-Score Range Over the Past 10 Years
Min: 5   Med: 7   Max: 9
Current: 7

During the past 13 years, the highest Piotroski F-Score of Chi Sheng Pharma & Biotech Co was 9. The lowest was 5. And the median was 7.

Chi Sheng Pharma & Biotech Co  (ROCO:4111) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Chi Sheng Pharma & Biotech Co Piotroski F-Score Related Terms


Chi Sheng Pharma & Biotech Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Chi Sheng Pharma & Biotech Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chi Sheng Pharma & Biotech Co Piotroski F-Score Chart

Chi Sheng Pharma & Biotech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 9.00 6.00 7.00 7.00

Chi Sheng Pharma & Biotech Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 7.00 8.00 6.00 7.00

ROCO:4111 vs ISRG, BDX, MDLN: Piotroski F-Score Comparison

For the Medical Instruments & Supplies subindustry, Chi Sheng Pharma & Biotech Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chi Sheng Pharma & Biotech Co Piotroski F-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Chi Sheng Pharma & Biotech Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Chi Sheng Pharma & Biotech Co's Piotroski F-Score falls into.


ROCO:4111
84GF Score
Chi Sheng Pharma & Biotech Co Ltd ROCO:4111
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was 38.755 + 34.743 + 45.125 + 45.657 = NT$164 Mil.
Cash Flow from Operations was 41.551 + 17.346 + 119.49 + 96.223 = NT$275 Mil.
Revenue was 319.606 + 367.758 + 342.135 + 346.981 = NT$1,376 Mil.
Gross Profit was 121.673 + 150.329 + 132.376 + 139.286 = NT$544 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was
(1749.63 + 1781.951 + 1841.255 + 1906.082 + 1937.777) / 5 = NT$1843.339 Mil.
Total Assets at the begining of this year (Dec24) was NT$1,750 Mil.
Long-Term Debt & Capital Lease Obligation was NT$6 Mil.
Total Current Assets was NT$925 Mil.
Total Current Liabilities was NT$461 Mil.
Net Income was 23.128 + 20.603 + 20.172 + 46.73 = NT$111 Mil.

Revenue was 267.2 + 282.519 + 284.253 + 331.465 = NT$1,165 Mil.
Gross Profit was 81.382 + 91.672 + 98.174 + 125.955 = NT$397 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was
(1766.103 + 1776.013 + 1788.481 + 1711.73 + 1749.63) / 5 = NT$1758.3914 Mil.
Total Assets at the begining of last year (Dec23) was NT$1,766 Mil.
Long-Term Debt & Capital Lease Obligation was NT$7 Mil.
Total Current Assets was NT$785 Mil.
Total Current Liabilities was NT$373 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Chi Sheng Pharma & Biotech Co's current Net Income (TTM) was 164. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Chi Sheng Pharma & Biotech Co's current Cash Flow from Operations (TTM) was 275. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=164.28/1749.63
=0.09389414

ROA (Last Year)=Net Income/Total Assets (Dec23)
=110.633/1766.103
=0.06264244

Chi Sheng Pharma & Biotech Co's return on assets of this year was 0.09389414. Chi Sheng Pharma & Biotech Co's return on assets of last year was 0.06264244. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Chi Sheng Pharma & Biotech Co's current Net Income (TTM) was 164. Chi Sheng Pharma & Biotech Co's current Cash Flow from Operations (TTM) was 275. ==> 275 > 164 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=6.426/1843.339
=0.00348607

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=7.09/1758.3914
=0.00403209

Chi Sheng Pharma & Biotech Co's gearing of this year was 0.00348607. Chi Sheng Pharma & Biotech Co's gearing of last year was 0.00403209. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=925.116/461.001
=2.00675487

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=784.617/372.801
=2.10465369

Chi Sheng Pharma & Biotech Co's current ratio of this year was 2.00675487. Chi Sheng Pharma & Biotech Co's current ratio of last year was 2.10465369. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Chi Sheng Pharma & Biotech Co's number of shares in issue this year was 60.898. Chi Sheng Pharma & Biotech Co's number of shares in issue last year was 60.435. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=543.664/1376.48
=0.39496687

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=397.183/1165.437
=0.34080178

Chi Sheng Pharma & Biotech Co's gross margin of this year was 0.39496687. Chi Sheng Pharma & Biotech Co's gross margin of last year was 0.34080178. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=1376.48/1749.63
=0.78672634

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=1165.437/1766.103
=0.65989186

Chi Sheng Pharma & Biotech Co's asset turnover of this year was 0.78672634. Chi Sheng Pharma & Biotech Co's asset turnover of last year was 0.65989186. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+0+0+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Chi Sheng Pharma & Biotech Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 7 mean?
Chi Sheng Pharma & Biotech Co (ROCO:4111) has a Piotroski F-Score of 7 as of Jul. 15, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Chi Sheng Pharma & Biotech Co and its competitors. This is near median its historical median of 7.00. Over the past decade, Chi Sheng Pharma & Biotech Co's Piotroski F-Score has ranged from 5.00 to 9.00. According to the industry distribution chart, Chi Sheng Pharma & Biotech Co ranks #60 out of 802 companies in the Medical Devices & Instruments industry, placing it in the top 7.5%.
Is Chi Sheng Pharma & Biotech Co's Piotroski F-Score too high?
Chi Sheng Pharma & Biotech Co's current Piotroski F-Score of 7 is near median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 9.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Chi Sheng Pharma & Biotech Co's value of 7 is 40% above this industry median. Based on the distribution chart, Chi Sheng Pharma & Biotech Co ranks #60 out of 802 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Chi Sheng Pharma & Biotech Co has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chi Sheng Pharma & Biotech Co's Piotroski F-Score compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Chi Sheng Pharma & Biotech Co ranks #60 out of 802 companies for Piotroski F-Score. This places Chi Sheng Pharma & Biotech Co in the top 8% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Chi Sheng Pharma & Biotech Co's value of 7 is 40% above this benchmark. Historically, Chi Sheng Pharma & Biotech Co's own Piotroski F-Score has ranged from 5.00 to 9.00 over the past decade. While the company's 10-year median is 7.00 vs. the industry median of 5.00, Chi Sheng Pharma & Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 802 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chi Sheng Pharma & Biotech Co's current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Chi Sheng Pharma & Biotech Co and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chi Sheng Pharma & Biotech Co's current Piotroski F-Score is 7, which is near median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chi Sheng Pharma & Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Chi Sheng Pharma & Biotech Co (ROCO:4111) is currently considered Fairly Valued. The stock's GF Value™ is NT$33.14, compared to a current price of NT$30.15 — trading 9% below its estimated fair value. The current Piotroski F-Score is 7, which is near median its 10-year median of 7.00 and 40% above the Medical Devices & Instruments industry median of 5.00. Chi Sheng Pharma & Biotech Co's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Chi Sheng Pharma & Biotech Co (ROCO:4111), the current Piotroski F-Score is 7 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chi Sheng Pharma & Biotech Co (ROCO:4111) Overvalued in 2026?

Based on GuruFocus' analysis, Chi Sheng Pharma & Biotech Co stock appears to be undervalued. The current stock price of NT$30.15 is trading 9% below its estimated GF Value™ of NT$33.14. GuruFocus considers Chi Sheng Pharma & Biotech Co to be Fairly Valued.

Key valuation signals for ROCO:4111:

  • Piotroski F-Score: 7 (near median its 10-year median of 7.00)
  • GF Value™: NT$33.14 vs. price of NT$30.15 (9% below fair value)
  • GF Score™: 84/100 with 1 warning sign
  • Industry Position: 40% above the Medical Devices & Instruments median (#60 of 802)

No single metric tells the full story. See the ROCO:4111 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Chi Sheng Pharma & Biotech Co Business Description

Address No. 3, Shijian Road, Hsin Chu Industrial Park, Hsinchu County, Hukou, TWN, 30316
Chi Sheng Pharma & Biotech Co Ltd manufactures and distributes medical medicines and equipment in Taiwan. It offers injections, including hemodialysis solutions, amino acid injections, vitamin injections, and externally applied medicines.
84GF Score

Get the complete analysis for ROCO:4111

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$30.15
Price
NT$33.14
GF Value